Prostate Cancer

The primary focus of the trial is to evaluate the incidence of treatment-emergent and serious side effects in patients receiving either the novel drug alone or in combination with Keytruda.

From liver cancer survivor planning to run the upcoming Boston Marathon with his organ donor to a common HIV drug showing promise in treating colorectal cancer, here’s what’s happening in the cancer space this week.

A recently FDA-approved drug offers patients with metastatic castration-resistant prostate cancer a newer treatment that improves survival, but is not curative of the disease, which means that more research is needed, according to an expert.

Patients with PSMA-positive metastatic castration-resistant prostate cancer can now be treated with Pluvicto, which may provide hope to an unmet need in this patient population.

From two celebrity deaths due to cancer to leading American cancer organizations coming together to help patients with cancer fleeing Ukraine, here’s what’s happening in the cancer space this week.

In a news release, Merck advised patients enrolled on the trial to consult with their health care provider regarding their treatment.

Regardless of a man’s age, providing care to a partner or family member with cancer has been shown to take a drastic toll on their health. To make matters worse, research shows many men struggle in silence.

Patients treated with Lutetium-177 PSMA-617 tended to experience improvements in quality of life related to the aches and pains that can come from bone metastases.

Patients with nonmetastatic castration-resistant prostate cancer who were taking other medications or had health complications still derived a survival benefit from treatment with Nubeqa, research showed.

A phase 1/2a clinical trial examining the effects of a treatment called LAVA-1207 for patients with metastatic prostate cancer has now begun.

One expert noted that patients with prostate cancer can take a few months to make an informed treatment decision without impacting their long-term outcomes.

The STELLAR-002 trial is currently underway to examine the combination of XL092, an experimental tyrosine kinase inhibitor, in combination with immuno-oncology therapies for patients with advanced solid tumors.

Prostate cancer survivors are encouraged to include their partners in interventions to improve sexual function after treatment — and, as study results show, it is better to have these conversations with providers sooner rather than later.

Sexual dysfunction may often happen after prostate cancer treatment, and the results of one study shown that an online program for both the patient and their partner may help in this aspect of recovery.

Additional advancements in how radical prostatectomy is performed are needed to improve other urinary outcomes such as good urinary function and social incontinence.

The pharmaceutical company announced preliminary results on a phase 3 trial, which demonstrated that Nubeqa with docetaxel and androgen deprivation therapy may improve overall survival in men with metastatic hormone-sensitive prostate cancer.

With recently revised treatment guidelines, doctors may be more likely to recommend active surveillance to men with low-risk prostate cancer.

Hypofractionated radiation for nearly five weeks in men with prostate cancer after surgery may have similar results without added side effects compared with radiation therapy for a standard duration of seven weeks.

A man reflects on slight symptoms he was not concerned about leading up to his prostate cancer diagnosis.

The first patient was enrolled in a phase 2 clinical trial for the treatment of hormone-sensitive advanced prostate cancer.

Treatments for bladder, colorectal and prostate cancer may cause sexual dysfunction in men. Here, an expert provides insight into how patients and survivors may improve their sexual health.

It is important that the whole community understand that basic research and clinical trials can continue to improve outcomes for patients with genitourinary cancer.

In this special issue of CURE®, we spoke with patients and health care providers about fertility issues, treatment advancements and other topics related to kidney, prostate, testicular and bladder cancers.

The prescription of systemic cancer therapies varies based on a patient’s age, comorbidities, cancer stage and other variables, according to recent research.

Clinical trials that are designed to ask patients with bladder, kidney and prostate cancer about their smoking status may help patients better understand what to expect from their treatment based on their smoking habits.